

## DESCRIPTION

<b>Species Reactivity</b>	Human
<b>Specificity</b>	Detects human PD-L2/B7-DC in direct ELISAs and Western blots. In direct ELISAs, approximately 50% cross-reactivity with recombinant mouse PD-L2 is observed and less than 1% cross-reactivity with recombinant human (rh) B7-1, rhB7-2, rhB7-H1, rhB7-H2, rhB7-H3, rhB7-H3b and recombinant rat B7-1 is observed.
<b>Source</b>	Polyclonal Goat IgG
<b>Purification</b>	Antigen Affinity-purified
<b>Immunogen</b>	Mouse myeloma cell line NS0-derived recombinant human PD-L2/B7-DC Leu20-Pro219 Accession # Q9BQ51
<b>Endotoxin Level</b>	<0.10 EU per 1 µg of the antibody by the LAL method.
<b>Formulation</b>	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied as a 0.2 µm filtered solution in PBS.

## APPLICATIONS

**Please Note:** Optimal dilutions should be determined by each laboratory for each application. *General Protocols* are available in the *Technical Information* section on our website.

	Recommended Concentration	Sample
<b>Western Blot</b>	0.1 µg/mL	Recombinant Human PD-L2 Fc Chimera (Catalog # 1224-PL)
<b>Immunohistochemistry</b>	5-15 µg/mL	Immersion fixed paraffin-embedded sections of human lung
<b>Blockade of Receptor-ligand Interaction</b>	In a functional ELISA, 1-5 µg/mL of this antibody will block 50% of the binding of 500 ng/mL of Recombinant Human PD-1 Fc Chimera (Catalog # 1086-PD) to immobilized Recombinant Human PD-L2/B7-DC Fc Chimera (Catalog # 1224-PL) coated at 1 µg/mL (100 µL/well). At 30 µg/mL, this antibody will block >90% of the binding.	

## PREPARATION AND STORAGE

<b>Reconstitution</b>	Reconstitute at 0.2 mg/mL in sterile PBS.
<b>Shipping</b>	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
<b>Stability &amp; Storage</b>	<b>Use a manual defrost freezer and avoid repeated freeze-thaw cycles.</b> <ul style="list-style-type: none"> <li>● 12 months from date of receipt, -20 to -70 °C as supplied.</li> <li>● 1 month, 2 to 8 °C under sterile conditions after reconstitution.</li> <li>● 6 months, -20 to -70 °C under sterile conditions after reconstitution.</li> </ul>

## BACKGROUND

T cells require a signal induced by the engagement of the T cell receptor and a "co-stimulatory" signal(s) through distinct T cell surface molecules for optimal T cell activation and tolerance. Members of the B7 superfamily of counter-receptors were identified by their ability to interact with co-stimulatory molecules found on the surface of T cells. Members of the B7 superfamily include B7-1 (CD80), B7-2 (CD86), B7-H1 (PD-L1), B7-H2 (B7RP-1), B7-H3, and PD-L2 (B7-DC) (1). B7 proteins are immunoglobulin (Ig) superfamily members with extracellular Ig-V-like and Ig-C-like domains and short cytoplasmic domains. Among the family members, they share from 20-40% amino acid (aa) sequence identity. The cloned human PD-L2 cDNA encodes a 273 aa type I membrane precursor protein with a putative 20 aa signal peptide, a 201 aa extracellular region containing one V-like and one C-like Ig domain, a 24 aa transmembrane region, and a 28 aa cytoplasmic domain. The extracellular domains of mouse and human PD-L2 share approximately 70% aa sequence identity (2). PD-L2 is one of two ligands for programmed death-1 (PD-1), a member of the CD28 family of immuno-receptors. The other identified ligand is PD-L1. Human PD-L1 and PD-L2 share approximately 41% aa sequence identity and have similar functions. PD-L2 is broadly expressed in tissues. Highest expression was detected by Northern blot analysis in heart, placenta, liver, pancreas, spleen, and lymph node. Lower amounts of expression were observed in lung, smooth muscle, and thymus. Expression of PD-L2 on antigen presenting cell has been examined in detail. Resting B cells, monocytes and dendritic cells do not express PD-L2, expression however can be induced by LPS or BCR activation in B cells, INF-γ treatment in monocytes, or LPS plus INF-γ treatment of dendritic cells. PD-L2 expression is also up regulated in a variety of tumor cell lines. On previously activated T cells, PD-L2 interaction with PD-1 inhibits TCR-mediated proliferation and cytokine production, suggesting an inhibitory role in regulating immune responses. In contrast, a co-stimulatory function for the PD-L2 on resting T cells activated with sub-optimal TCR signals has also been reported (3).

## References:

1. Coyle, A.J. and J-C. Gutierrez-Ramos (2001) *Nature Immunol.* **2**:203.
2. Latchman Y. *et al.* (2001) *Nature Immun.* **2**:261.
3. Carreno, B.M. and M. Collins (2002) *Annu. Rev. Immunol.* **20**:29.